{
    "root": "341ca833-1ddb-f030-e063-6294a90a2dd9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Doxepin",
    "value": "20250501",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "DOXEPIN HYDROCHLORIDE",
            "code": "3U9A0FE9N5"
        }
    ],
    "indications": "Doxepin Tablets are indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration.",
    "contraindications": "The dose of Doxepin Tablets should be individualized.",
    "warningsAndPrecautions": "Doxepin Tablets 3 mg are white to off white, oval shaped tablets, with \"P\" on one side and \"012\" on the other side, and are supplied as:\n                  \n                     NDC 72162-2474-3: 30 Tablets in a BOTTLE\n                  \n                  \n                  Store at controlled room temperature 20째 to 25째C (68째 to 77째F) [see USP Controlled Room Temperature]. Protect from light.\n                  \n                  Repackaged/Relabeled by:\n  \nBryant Ranch Prepack, Inc.\n  \nBurbank, CA 91504",
    "adverseReactions": "Hypersensitivity to doxepin hydrochloride, inactive ingredients, or other dibenzoxepines. (4.1) Co-administration with Monoamine Oxidase Inhibitors (MAOIs): Do not administer if patient is taking MAOIs or has used MAOIs within the past two weeks. (4.2) Untreated narrow angle glaucoma or severe urinary retention. (4.3)"
}